SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation, a drug discovery and development company, announced today the completion of a multinational phase 2a clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes mellitus. Statistical analysis of the trial data shows significant improvement of postprandial blood glucose levels and HbA1c with once daily dosing. There was no apparent pattern of drug related adverse events and PHX1149 demonstrated a tolerability profile comparable to placebo at all dose levels tested. The favorable tolerability data are consistent with the high selectivity of this compound, the low peak-to-trough pharmacokinetic characteristics and low cellular permeability.
